TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and, together with Teva Finance II and Teva Finance III, the “Issuers”) intend to offer USD-denominated Senior Notes (the “USD Notes” and, together with the Euro Notes, the “Notes”).
The offering of Notes is subject to, among other things, market conditions. Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redemptions of certain existing notes as further set out below (the “Conditional Redemptions”), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, for general corporate purposes, including the repayment of outstanding debt upon maturity, tender offer or earlier redemption.
In connection with the Conditional Redemptions, Teva intends to issue notices of conditional redemption pursuant to which it intends to redeem in accordance with the terms set forth in the relevant indentures: (i) all of the 6.750% Senior Notes due 2028 that are outstanding, (ii) all of the 7.875% Sustainability-Linked Senior Notes due 2029 that are outstanding, (iii) all of the 7.375% Sustainability-Linked Senior Notes due 2029 that are outstanding, (iv) up to $450,000,000 in principal amount of 4.750% Sustainability-Linked Senior Notes due 2027 and (v) up to €1,250,000,000 in principal amount of 4.375% Sustainability-Linked Senior Notes due 2030. The Conditional Redemptions are expected to be conditioned on the consummation of the offering. The offering, however, is not conditioned on the Conditional Redemptions. Teva may, in its sole discretion, decide to issue additional notices of conditional redemption and redeem certain of its other outstanding notes, or to amend the principal amounts to be redeemed under any of the foregoing notices, in each case in accordance with the terms set forth in the relevant indentures pursuant to which such notes were issued, although it is under no obligation to do so.
Net proceeds may be temporarily invested pending application for their stated purpose.
The Notes will be unsecured senior obligations of the Issuers and will be unconditionally guaranteed on a senior basis by Teva.
The offering and sale of the Notes will be made pursuant to our effective automatic shelf registration statement on Form S-3, including our base prospectus, filed with the Securities and Exchange Commission (the “SEC”) on February 7, 2025. The offering of these Notes will be made only by means of a prospectus supplement and accompanying base prospectus, which have been filed with the SEC. Before you invest, you should read the prospectus supplement and accompanying prospectus along with other documents that Teva has filed with the SEC and that are incorporated by reference into the prospectus supplement and accompanying base prospectus for more complete information about Teva and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at http://www.sec.gov. Alternatively, a copy of the prospectus supplement and accompanying base prospectus related to this offering may be obtained, when available, by contacting BNP PARIBAS, 16, boulevard des Italiens, 75009 Paris, France, Attention: Fixed Income Syndicate (emails: [email protected]); BNP Paribas Securities Corp., 787 Seventh Avenue, New York, New York 10019, United States of America, Attention: Debt Syndicate Desk (email: [email protected]); Citigroup Global Markets Europe AG or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, United States of America, Telephone: (800) 831-9146, E-mail: [email protected]; Goldman Sachs Bank Europe SE, Marienturm, Taunusanlage 9-10, 60329 Frankfurt am Main, Germany, Attention: High Yield Syndicate Desk (Tel: +49 69 7532 1000, Fax: +44 (0)207 774 2330); J.P. Morgan SE, Taunustor 1 (TaunusTurm), 60310 Frankfurt am Main, Germany, Attention: Head of EMEA Capital Markets Group (email: [email protected]) and J.P. Morgan Securities LLC, 270 Park Avenue, New York, New York 10017, United States of America, Attention: Investment Grade Syndicate Desk, Tel: (212) 834-6081).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: completion of the offering of senior notes and conditional redemptions for certain outstanding notes; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026, in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward Looking Statements,” and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
It may be unlawful to distribute this press release in certain jurisdictions. This press release is not for distribution in Canada, Japan or Australia. The information in this press release does not constitute an offer of securities for sale in Canada, Japan or Australia.
The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (“EEA”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); or (ii) a customer within the meaning of Directive 2016/97/EU (as amended, the “Insurance Distribution Directive”), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129. Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.
The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investors in the United Kingdom. For these purposes, a retail investor means a person who is neither: (i) a professional client, as defined in point (8) of the UK MiFIR; nor (ii) a qualified investor as defined in paragraph 15 of Schedule 1 to the POATRs. Consequently, no disclosure document required by DISC for offering or selling, or distributing the Notes or otherwise making them available to retail investors in the UK has been prepared and, therefore, offering or selling, or distributing the notes or otherwise making them available to any retail investor in the UK may be unlawful under the DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.
Promotion of the Notes in the United Kingdom is restricted by the FSMA, and accordingly, the Notes are not being promoted to the general public in the United Kingdom. This announcement is for distribution only to, and is only directed at, persons who are (i) outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (iii) high net worth entities, and other persons to whom they may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). The Notes will only be available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be engaged in only with, relevant persons. This announcement is directed only at relevant persons and must not be acted on or relied on by anyone who is not a relevant person.
The Notes have not, may not and will not be offered, sold or delivered in the Netherlands, other than to qualified investors (as defined in Regulation (EU) 2017/1129).
The Notes have not, may not and will not be offered, sold or delivered in Israel, other than to persons who qualify as one of the types of investors listed in the First Addendum to the Israeli Securities Law, subject to and in accordance with the requirements set forth in the First Addendum to the Israeli Securities Law.
Teva oznámila, že TEV-408 ve studii fáze 2a splnil primární cíl a statisticky významně zabránil poškození střev vyvolanému lepkem u pacientů s celiakií oproti placebu po jedné subkutánní dávce. Přípravek byl dosud dobře snášen bez bezpečnostních signálů.
Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage vs placebo following a single subcutaneous dose.TEV ‘408 was well-tolerated with no safety signals observed to date.Together with the vitiligo program, the celiac disease topline results further support TEV ‘408 as a potential pipeline-in-a-product opportunity in multiple diseases. Teva will hold an investor call and live webcast today,
Wednesday, September 2, 2026, at 8:00 a.m. ET to discuss these data.
TEL AVIV, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8. TEV ‘408 was well-tolerated, with no safety signals observed to date.
“A strict gluten-free diet has long been the only option for people living with celiac disease. Yet, even with strict adherence to a gluten-free diet, many continue to experience symptoms, intestinal damage and a significant impact on their daily lives,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “These results underscore the potential to move beyond managing gluten exposure and address celiac disease at its biological source. They also strengthen our confidence in targeting the IL-15 pathway as an approach to reducing immune-driven intestinal damage.”
The ongoing randomized, placebo-controlled study enrolled 50 adult participants with celiac disease on a gluten-free diet (GFD) with minimal intestinal damage at baseline as measured by the villous height-to-crypt depth ratio (Vh:Cd ≥2.0) and symptoms. Two weeks after receiving a single dose of TEV ‘408, participants began a six-week daily gluten challenge (GC). The study assessed biopsy-based measures of intestinal damage and inflammation along with patient-reported symptoms. At week 8 (the end of the GC) TEV ‘408:
Showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo, as measured by the trial’s primary endpoint of Vh:Cd ratio with a least squares (LS) mean change from baseline of -0.43 compared with -0.88 for placebo (treatment difference of 0.45, 95% CI: (0.06, 0.84), p<0.05).Showed a favorable effect on intestinal inflammation as measured by density of intraepithelial lymphocytes (IELs) compared with placebo; the LS Mean change from baseline in the density of IELs, was an increase of 27.60 for placebo compared to 0.37 for TEV ‘408 treated participants (treatment difference of -27.23, 95% CI: (-39.67, -14.79)).Demonstrated lower GI symptom scores versus placebo, as assessed using the Celiac Disease Symptom Diary (CDSD), a patient-reported outcome (PRO).Was well-tolerated with no emerging safety signals. Additional analyses from the ongoing Phase 2a study are underway. Teva plans to present further data from the study at a future scientific meeting.
Teva Investor Call
Teva will hold an investor call and live webcast today, Wednesday, September 2, 2026, at 8:00 a.m. ET/ 2:00 p.m. CET to discuss these data. To participate, please register in advance here. To access a live webcast of the presentation, visit Teva’s Investor Relations website. An archived version of the webcast will be available 24 hours after the end of the live discussion.
About TEV ‘408
TEV ‘408, discovered by Teva, is an investigational human monoclonal antibody designed to inhibit interleukin-15 (IL-15), a cytokine involved in immune-mediated pathways. TEV ‘408 has a high affinity and potency (in vitro) with a prolonged half-life that supports the potential for convenient subcutaneous dosing.
TEV ‘408 is being studied as a potential therapy for celiac disease in a Phase 2a study and was granted Fast Track designation in that indication by the U.S. FDA in May 2025. By blocking IL-15 activity, TEV ‘408 aims to reduce the IL-15-driven intestinal inflammation and damage that are characteristic of celiac disease.
TEV ‘408 is also being evaluated in a Phase 1b study as a treatment for vitiligo. Following encouraging results from the ongoing Phase 1b study in vitiligo, Teva is advancing the investigational asset into a Phase 2b study in vitiligo. By blocking IL-15 activity, TEV ‘408 aims to reduce the immune-mediated destruction of melanocytes (pigment-producing cells) resulting in white patches on the skin characteristic of vitiligo.
Teva entered a strategic funding agreement with Royalty Pharma in January 2026. Under the agreement, Teva is eligible to receive up to $500 million to accelerate the clinical development of TEV ‘408. If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV ‘408.
About Celiac Disease
Celiac disease is a serious autoimmune disease in which exposure to gluten triggers an immune response that damages the small intestine. It affects approximately 1% of the global population, or more than three million people in the U.S. alone, although many individuals remain undiagnosed. Celiac disease can cause chronic digestive symptoms, fatigue, nutrient deficiencies, and other health complications that can significantly impact daily life.
There are currently no approved therapies for celiac disease. A strict gluten-free diet (GFD) remains the standard of care, yet even with careful adherence, patients may continue to experience symptoms, reduced quality of life, and ongoing intestinal inflammation or damage due to inadvertent gluten exposure. For people living with celiac disease, managing the condition often requires constant vigilance around meals, travel, work, and social activities, creating significant daily burden. The limitations of current management approaches underscore the need for therapies that address the underlying drivers of disease and improve outcomes for patients.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize TEV-’408 for the treatment of celiac disease and for the treatment of vitiligo; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors,” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2392ceaa-b1f3-44a8-bd7e-4c775053e093
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Ant... Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Ant...
Teva oznámila s administrativou Donalda Trumpa záměr snížit cenu vybraných léků pro pacienty v programu Medicaid. Dohoda má zároveň podpořit investice do inovací a výroby v USA.
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities.
“Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow,” said Chris Fox, President, Teva USA. “Teva built its business around delivering affordable medicines to Americans, and we share the Administration’s commitment to improve access to more affordable medicines while investing in scientific innovation and domestic manufacturing capabilities in the U.S.”
Teva remains in active discussions with the Trump Administration to strike a deal anchored in all four of the President’s drug pricing priorities. If an agreement is reached, Teva would align U.S. Medicaid pricing for select medicines with pricing in leading developed markets through the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework. The agreement also would include a prospective Most-Favored-Nation (MFN) commitment for applicable future innovative product launches. Additionally, Teva has offered a dedicated reserve of certain active pharmaceutical ingredients (API) in support of public health needs and continued investment into U.S. pharmaceutical manufacturing capabilities. Conditions of the negotiation to reach a final agreement remain confidential.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage; U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including most-favored-nation pricing and related regulatory efforts; our ability to execute the agreement with the U.S. administration to lower the cost of select medicines for patients in the U.S. covered by Medicaid while supporting continued investment in scientific innovation and healthcare system resilience; changes in U.S. administration; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva podala nabídku na koupi vybraných aktiv BioXcel Therapeutics včetně Igalmi v aukci řízené soudem. Zaplatila by 57,5 milionu USD předem a až 67,5 milionu USD v podmíněných platbách.
Key Takeaways Teva bids for BioXcel assets, including Igalmi, in a court-supervised auction process.BXCL501 is under FDA review for potential at-home treatment of acute agitation in adults.Teva would pay $57.5 million upfront, with up to $67.5 million in contingent payments. Teva Pharmaceutical Industries Limited (TEVA - Free Report) announced it has made a bid to acquire certain assets of BioXcel Therapeutics, including the Igalmi (dexmedetomidine) sublingual film.
Igalmi, the currently approved formulation of dexmedetomidine sublingual film, is indicated for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorder in adults when administered under the supervision of a healthcare provider.
Teva has agreed to serve as the “stalking horse bidder” in a court-supervised auction process for the assets. The proposed transaction does not involve the complete acquisition of BioXcel as a whole. However, Teva would acquire the assets if it is selected as the successful bidder, subject to bankruptcy court approval, potential higher bids and customary closing conditions.
Year to date, shares of Teva have risen 16.7% compared with the industry’s rise of 6.4%.
Image Source: Zacks Investment Research
TEVA’s Potential Neuroscience OpportunityThe key asset is BXCL501, a novel, orally dissolving dexmedetomidine sublingual film that is currently under FDA review for potential at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. A decision from the regulatory body is expected on Nov. 14, 2026.
If approved, the product could potentially become the first FDA-approved at-home treatment for this condition, providing an option for patients outside traditional healthcare or hospital settings.
The proposed transaction would give Teva worldwide rights to the related assets, including the investigational formulation under FDA review for potential outpatient use.
What's Driving TEVA’s Interest?Under the above agreement, Teva would pay $57.5 million upfront for the assets, with the potential for up to an additional $67.5 million in contingent payments. The additional payments include time-based payments tied to the timing of FDA approval, potential approval delays and specified sales milestones.
The proposed transaction fits Teva’s strategy of pursuing assets that offer a strategic fit, address patient needs and have the potential to generate long-term value. Management expects that, if successful, the deal would strengthen its neuroscience portfolio while maintaining a disciplined approach to capital allocation and risk.
The move underscores Teva’s ongoing focus on targeted business development as part of its Pivot to Growth strategy.
Teva recently expanded its neuroscience pipeline through the acquisition of Emalex Biosciences, adding ecopipam, an investigational therapy being developed for treating pediatric Tourette syndrome.
In August 2026, the FDA accepted the new drug application ("NDA") seeking approval for ecopipam for the treatment of pediatric patients with Tourette syndrome.
With the FDA granting priority review to the NDA, a decision from the regulatory body is expected in late first quarter of 2027. If approved, ecopipam could become the first new Tourette syndrome therapy in more than 10 years and the first novel mechanism of action in more than 50 years.
TEVA's Zacks Rank & Stocks to ConsiderTeva currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Anika Therapeutics (ANIK - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 7.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 earnings per share have risen from 41 cents to $1.05, while estimates for 2027 have increased from 46 cents to 95 cents during the same time. ANIK’s shares have surged 119.6% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday’s premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
This news comes amidst a mixed market backdrop, with S&P 500 futures showing a slight loss of 0.03%.
Aurinia (AUPH) Settles Patent Litigation With TevaUnder the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the U.S. of its generic voclosporin product.
The settlement further provides that Teva may launch its generic voclosporin product no earlier than Dec. 7, 2036, unless certain defined contingencies occur earlier.
In January 2021, Aurinia introduced Lupkynis (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis.
The company is also developing aritinercept, a dual inhibitor of B cell-activating factor and a proliferation-inducing ligand for autoimmune diseases.
Read Next
AUPH Technical Outlook: Trend, Momentum And Key LevelsThe stock has shown a solid performance over the past year, gaining approximately 34.64%.
Currently, it is trading above its 20-day simple moving average (SMA) of $15.31, which indicates a bullish short-term trend. The 50-day SMA is at $15.89, suggesting that while the stock is performing well, it still has some resistance to overcome in the medium term.
The moving average convergence divergence (MACD) is above its signal line, indicating that downside pressure is easing and momentum is improving. This suggests a potential for further upward movement if the current trend continues.
Key Resistance: $19.25 — This level is significant as it marks the 52-week high, which could act as a barrier to further price increases. Key Support: $15.31 — This level aligns with the 20-day SMA, providing a cushion for the stock in case of a pullback. How Aurinia (AUPH) Ranks On Value And MomentumBelow is the Benzinga Edge scorecard for Aurinia Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:
Value: 63.91 — Indicates a relatively favorable valuation compared to peers. Momentum: 71.77 — Suggests that the stock is currently outperforming the broader market. The Verdict: Aurinia Pharmaceuticals’s Benzinga Edge signal reveals a balanced profile with strong momentum and favorable value indicators. This positioning may attract investors looking for growth opportunities in the biopharmaceutical sector.
AUPH Stock Price Activity: Aurinia Pharmaceuticals shares were up 2.66% at $16.60 during premarket trading on Thursday, according to Benzinga Pro data.
FDA přijala žádost Teva o registraci ecopipamu a udělila mu prioritní přezkum pro léčbu dětských pacientů s Touretteovým syndromem. Pokud bude schválen, půjde o první novou léčbu po více než 10 letech.
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designationNDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b dataIf approved, ecopipam would be the first new treatment option indicated for pediatric patients with Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years1 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam, with a targeted action (PDUFA) date late in the first quarter of 2027. Ecopipam is a first-in-class investigational therapy for the treatment of pediatric patients with Tourette syndrome. This milestone advances Teva’s Pivot to Growth strategy by utilizing the company’s expertise in neuroscience to support patients, particularly in areas where there is high unmet need.
Tourette syndrome is a debilitating neuro-developmental condition impacting approximately 100,000 children and adolescents nationwide.2 Only half of these patients are treated with prescription medication for this condition, and only 20-30 percent remain on therapy after one year. Despite the current treatment options available, many patients continue to experience inadequate control or treatment-limiting side effects.3 This patient experience underscores the urgent need for new prescription drug options and reinforces Teva’s commitment to expanding access to innovative neuroscience treatments for underserved patient populations.3
“Ecopipam’s NDA acceptance is an important milestone that advances Teva’s Pivot to Growth strategy and brings us closer to addressing the unmet needs of children and their families affected by Tourette syndrome,” said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer of Teva. “If approved, ecopipam would be the first new therapy for Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years, offering patients and families a long-awaited new treatment option.”
The NDA acceptance for ecopipam is supported by positive Phase 2b and 3 data. In the Phase 2b study, patients receiving ecopipam experienced a reduction in tic severity, with statistically significant and clinically meaningful improvement in the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) vs. placebo at Week 12 (P = 0.01).4 Durability of efficacy was shown in participants who subsequently enrolled in a Phase 2b open-label extension (OLE) study.5
The Phase 3 randomized withdrawal study, recently published in JAMA Neurology,6 further demonstrated maintenance of efficacy with ecopipam. For the primary endpoint, pediatric ecopipam responders compared to placebo had a 53% decreased risk of relapse over 12 weeks (p=0.008).6
Across the Phase 2b, Phase 2b OLE and Phase 3 clinical trials, no clinically meaningful changes were observed across the following areas with ecopipam use:4,5,6,7
Body weight and Body Mass Index (BMI) Z-ScoreVitals and laboratory measures, including metabolic parametersElectrocardiogram (ECG) measurementsDrug-induced movement disorders (DIMD) as measured by the Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS) or Extrapyramidal Symptom Rating Scale (ESRS)Measures of psychiatric comorbidities Ecopipam was generally well-tolerated and the most common adverse events in pediatric patients with Tourette syndrome were headache, insomnia, fatigue, somnolence, tics, anxiety, nausea and restlessness.4,5,6
Teva remains deeply committed to advancing this clinical program and, if approved, delivering a long-awaited new treatment option to pediatric patients with Tourette syndrome who have historically relied on treatment options primarily developed for other conditions.
About Tourette Syndrome
Tourette syndrome is a chronic neuro-developmental disorder characterized by involuntary motor and vocal tics beginning in childhood, often between 5 and 10 years of age.2 For people living with Tourette syndrome, symptoms can be frequent, visible, and disruptive, affecting everyday life.2
About Ecopipam and Its Clinical Program
Ecopipam is a first-in-class investigational therapy designed to block dopamine signaling at the D1 receptor. D1 receptor hypersensitivity may contribute to repetitive and compulsive behaviors associated with Tourette syndrome.
Ecopipam was granted Priority Review by the FDA with Orphan Drug designation for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation is reserved for patient populations of 200,000 or fewer.
The D1AMOND Phase 2b Trial was a 12-week randomized, double-blind, placebo-controlled trial that studied 153 pediatric participants across 68 sites in North America and Europe. The primary efficacy endpoint was the change in the YGTSS-TTS, i.e., sum of the motor and vocal tic scores, from baseline to end of therapy.4 The associated Phase 2b open-label extension enrolled 121 pediatric subjects from the Phase 2b trial and followed them for up to 12 months’ duration to evaluate the long-term safety and tolerability of ecopipam.5 The subsequent D1AMOND Phase 3 Trial was a double-blind, placebo-controlled, randomized withdrawal trial enrolling a total of 216 pediatric and adult participants into an open-label stabilization period and randomizing 104 participants (90 pediatric, 14 adult) across 77 sites in North America and Europe. The objective of this study was to evaluate the maintenance of efficacy of ecopipam in pediatric and adult responders utilizing the YGTSS-TTS change from randomization or increased Tourette-specific care to determine relapse.6 While this Phase 3 trial included adult participants, the accepted NDA and resulting indication sought by Teva are exclusively for pediatric patients.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully develop, obtain regulatory approval for and commercialize ecopipam; our ability to successfully compete in the marketplace including our ability to develop and commercialize ecopipam and additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors,” “Other Information” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
U.S. Food and Drug Administration (FDA) Approval Records: Haloperidol (1969), Pimozide (1984), Aripiprazole (2014); Pringsheim, T., et al. (2019). The pharmacological management of tic disorders: an updated practice guideline. Neurology.CDC | Tourette Syndrome | Data and Statistics on Tourette Syndrome, 2024; Mayo Clinic | Tourette Syndrome – Diagnosis and treatment, 2025.Tomczak KK et al. High Rates of Discontinuation of D2 Receptor Antagonists as Treatment of Tourette Syndrome in Children: A Retrospective Database Analysis American Academy of Neurology (AAN) Annual Meeting Poster, 2025.Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette Syndrome: A Randomized Trial. Pediatrics. 2023;151(2):e2022059574. doi:10.1542/peds.2022-059574Gilbert DL, Kim DJB, Miller MM, et al. Safety and Effect of 12-Month Ecopipam Treatment in Pediatric Patients with Tourette Syndrome. Mov Disord Clin Pract. 2025;12(8):1157-1166. doi:10.1002/mdc3.70091.Gilbert DL, Atkinson SD, Kim DJB, et al. Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026;83(7):645–653. doi:10.1001/jamaneurol.2026.1431Data on file. Teva Media Inquiries [email protected]
Teva za poslední týden vzrostla asi o 12,3 % po smíšených výsledcích za 2. čtvrtletí. Tržby 4,1 miliardy USD překonaly odhad, i když upravený zisk na akcii 0,02 USD zaostal.
Teva Pharmaceutical (TEVA -1.13%) stock closed out the last week of trading with significant gains, rising roughly 12.3% across the stretch. The S&P 500 gained 0.2% over the same period, and the Nasdaq Composite was up approximately 0.5%.
Teva published its second-quarter report after the market closed on July 29, posting mixed results. While earnings for the period came in below Wall Street's target, the company delivered some news that excited investors.
Image source: Getty Images.
Teva's Q2 results at a glance With its Q2 report, Teva announced non-GAAP (adjusted) earnings of $0.02 per share -- a performance that fell far short of the average analyst estimate's call for adjusted earnings per share of $0.11 in the period. Meanwhile, sales in the period came in at $4.1 billion and surpassed the average analyst target by roughly $70 million. The generic drug leader's revenue was still down roughly 1% year over year in the period, but the decline was softer than expected -- and investors saw promise in the company's guidance and a significant new development for the stock.
Today's Change
(
-1.13
%) $
-0.40
Current Price
$
35.01
What's next for Teva? For the full-year period, Teva is guiding for adjusted earnings to be between $1.91 per share and $2.11 per share after accounting for closing and administrative costs stemming from its acquisition of Emalex. Meanwhile, the average analyst estimate had called per-share earnings of $2.16 for the year. The company also guided for sales to come in between $16.5 billion and $16.85 billion. For reference, the average Wall Street estimate had targeted sales of $16.63 billion.
With its Q2 report, Teva also announced that it was gearing up to have its stock listed directly on the New York Stock Exchange. As part of the initiative, the Israel-based company's American depositary receipts (ADRs) are set to be replaced with newly listed common stock. The new common stock is set to start trading on September 14, and the direct listing could help attract support from institutional investors and retail traders.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDT
Company Participants
Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence
Richard Francis - President, CEO & Director
Eric Hughes - Executive VP of Global R&D and Chief Medical Officer
Eliyahu Kalif - Executive VP & CFO
Conference Call Participants
Jason Gerberry - BofA Securities, Research Division
Umer Raffat - Evercore ISI Institutional Equities, Research Division
Louise Chen - Scotiabank Global Banking and Markets, Research Division
Yuchen Ding - Jefferies LLC, Research Division
David Amsellem - Piper Sandler & Co., Research Division
Ashwani Verma - UBS Investment Bank, Research Division
Glen Santangelo - Barclays Bank PLC, Research Division
Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Hello everybody, and welcome to the Q2 2026 Teva Pharmaceutical Industries Earnings Conference Call. My name is Elliot. I'll be coordinating your call today. [Operator Instructions] I would now like to hand over to Christopher Stevo.
Christopher Stevo
Senior Vice President of Investor Relations & Competitive Intelligence
Thank you, Elliot. Good morning and good afternoon, everyone. Thank you for joining us on our second quarter call. Obviously, our materials are posted to our website this morning, so please see those. And before I turn the call over to our CEO, Richard Francis, I'd like to remind everyone that we'll be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance.
Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent Forms 10-Q and 10-K filed with the SEC. Any statements that we make are only as of today, we undertake no obligation to update these
NYSE Listing TransitionTeva announces the replacement of its American Depositary Share (ADS) program with the direct listing of its ordinary shares on the New York Stock Exchange (NYSE).
ADSs will be exchanged on a one-for-one basis for ordinary shares, which commence trading on the NYSE on Monday, Sept. 14.
The transition aims to broaden Teva’s shareholder base, support its potential inclusion in leading indices, and optimize cost-of-capital.
Key Brands Offset Generic Drug WeaknessThe company reported adjusted earnings of two cents, missing the consensus of 25 cents.
Sales decreased 1% (-3% in local currency) to $4.142 billion, beating the Wall Street consensus of $4.047 billion. The decrease was due to lower revenues from generic products, primarily lenalidomide capsules.
The generic drug makers‘ key brands Austedo, Ajovy and Uzedy collectively grew 43% year over year in local currency to over $1 billion in revenues. Each brand grew at least 40% year over year in the quarter.
Generics global revenues were lower in the quarter mainly due to lower revenues from lenalidomide capsules (a generic version of Revlimid) in the U.S.; the biosimilars portfolio performed strongly and is on track to deliver $800 million in revenues by 2027.
The company, in its earnings conference call, said it is on track to meet its 2027 financial growth targets, with stable revenues despite challenges in the generics sector, and expects continued margin expansion driven by its innovative portfolio.
2026 Outlook and PipelineTeva expects fiscal 2026 adjusted earnings of $1.91-$2.11, including (66 cents) per share of 2026 Emalex expenses, unchanged from prior guidance.
The company marginally raised its 2026 sales guidance from $16.40 billion-$16.80 billion to $16.50 billion-$16.85 billion compared to the consensus of $16.618 billion.
Teva raised its 2026 revenue outlook for its key innovative brands, and now expects combined 2026 revenue of ~$3.7 billion, reflecting around 17% year-over-year growth at the midpoint.
The company has a robust pipeline with potential launches over the next five years, including olanzapine and ecopipam, and is increasing its biosimilars portfolio with 15 products currently in the market.
TEVA Stock Price Activity: Teva Pharmaceutical shares were up 9.25% at $34.60 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Teva Pharmaceutical Industries vykázala za čtvrtletí tržby 4,14 mld. USD, meziročně o 0,8 % méně, a EPS 0,02 USD oproti 0,66 USD loni. Tržby ale překonaly odhad Wall Street o 1,43 %.
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) reported $4.14 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 0.8%. EPS of $0.02 for the same period compares to $0.66 a year ago.
The reported revenue represents a surprise of +1.43% over the Zacks Consensus Estimate of $4.08 billion. With the consensus EPS estimate being $0.08, the EPS surprise was -75%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- International Markets- AJOVY: $49 million compared to the $31 million average estimate based on two analysts. The reported number represents a change of +145% year over year.Geographic Revenue- United States- Other: $84 million versus the two-analyst average estimate of $112.5 million. The reported number represents a year-over-year change of -24.3%.Geographic Revenue- International Markets- COPAXONE: $8 million compared to the $7.25 million average estimate based on two analysts. The reported number represents a change of +14.3% year over year.Geographic Revenue- International Markets- Generic products (including OTC and biosimilars): $419 million versus the two-analyst average estimate of $425.38 million. The reported number represents a year-over-year change of +2.2%.Geographic Revenue- International Markets- Other: $55 million compared to the $60.65 million average estimate based on two analysts. The reported number represents a change of 0% year over year.Geographic Revenue- Europe- AJOVY: $78 million compared to the $79.05 million average estimate based on two analysts. The reported number represents a change of +9.9% year over year.Geographic Revenue- Europe- COPAXONE: $49 million versus the two-analyst average estimate of $38.75 million. The reported number represents a year-over-year change of -2%.Geographic Revenue- Europe- Generic products (including OTC and biosimilars): $1.02 billion versus $1.1 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.5% change.Geographic Revenue- Europe- Other: $54 million versus $82.6 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -33.3% change.Geographic Revenue- Europe- Respiratory products: $58 million versus $57.59 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.Geographic Revenue- United States: $1.7 billion versus $1.65 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -20.9% change.Geographic Revenue- Europe: $1.26 billion compared to the $1.36 billion average estimate based on two analysts. The reported number represents a change of -2.7% year over year.View all Key Company Metrics for Teva Pharmaceutical Industries here>>>
Shares of Teva Pharmaceutical Industries have returned -6.5% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Teva letos pokračuje v oživení a za 12 měsíců vzrostla zhruba o 85 % díky posunu od generik ke značkovým lékům. Další růst může přinést duvakitug, který je ve fázi 3 klinických studií.
Year to date, Teva Pharmaceutical Industries (TEVA -1.25%) shares have continued to recover. Thanks to the company's shifting focus from generic to branded drugs, this pharmaceutical stock has surged by around 85% over the past 12 months.
Although Teva may be pulling back lately, don't assume the turnaround rally is over. In addition to success with its initial round of commercially successful branded pharmaceuticals, the company has one key candidate in the pipeline that could be on the verge of becoming a blockbuster drug.
Image source: Getty Images.
Teva's branded drug transformation As seen in Teva's first-quarter 2026 financials, generic drugs now barely make up a majority of the company's overall sales. Meanwhile, branded drugs, particularly recent hits like Austedo, Ajovy, and Uzedy, are experiencing mid-double-digit annual sales growth.
Management expects a drop in earnings per share (EPS), from $2.65 in 2025 to between $1.91 and $2.11 in 2026. However, much of this stems from the initial dilutive effect of Teva's recent acquisition of Emalex Biosciences. Starting next year, the anticipated launch of biosimilars, along with other factors, should contribute to a 30% increase in operating profit and adjusted EBITDA.. Furthermore, another emerging catalyst for Teva could drive the next big leap for shares.
Today's Change
(
-1.25
%) $
-0.39
Current Price
$
30.79
The duvakitug catalyst Next year, key drivers for the growth rebound include biosimilars, plus incremental sales growth for Teva's aforementioned flagship drugs. However, next year and beyond, duvakitug could be key to the company's further turnaround. The drug, which Teva co-developed with Sanofi, is currently in clinical trials as a treatment for ulcerative colitis and Crohn's disease.
If phase 3 clinical trial results prove as promising as recently released phase 2b findings, this drug could be on the fast track toward commercialization. Management has previously guided for duvakitug to reach between $2 billion and $5 billion in peak annual sales. Considering this, any progress with duvakitug could drive yet another massive rally, especially as the stock sells for less than 10 times estimated 2027 earnings. This strongly suggests taking advantage of near-term weakness by making this stock a long-term buy.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Teva se přesouvá od generik k novým lékům a Wall Street na ni má nákupní doporučení. Analytici vidí podle 12měsíčních cílů potenciál růstu o 28 % až 60 %.
Companies must evolve to stay relevant in the pharmaceutical industry. Teva Pharmaceutical Industries (TEVA -1.19%) is in the midst of its own transformation, from making generic drugs and biosimilars to novel drugs that are beginning to deliver growth and profits that are catching Wall Street's eye.
Every single Wall Street analyst polled by CNN Business currently has a buy rating on the pharmaceutical stock. Based on 12-month price targets, Teva could have anywhere from 28% to 60% upside from its current price, according to the analysts.
It seems like a bold call, considering the broader stock market has left the stock in the dust. Teva is down 40% over the past decade. But sometimes, these comeback stories produce the biggest returns. Here's why Wall Street analysts are right to be bullish about the stock right now.
Image source: Getty Images.
Teva is pivoting from generics to boost growth For a while, Teva had specialized in generics and biosimilars. Generic drugs are often simple formulations that typically sell at low margins. CEO Richard Francis took over in January 2023. He has helped guide the company further into developing novel drugs. This is a riskier path because drug development is expensive and many drugs fail to reach the market. However, a successful drug enjoys years of patent protection and can generate millions, even billions, of high-margin dollars in sales.
Today's Change
(
-1.19
%) $
-0.37
Current Price
$
30.81
Revenue from generic drugs and biosimilars was $612 million in the first quarter of 2026, down 28% from a year ago on weaker generic sales. Generics and biosimilars accounted for 40% of Teva's total sales in Q1, and management expects biosimilars to continue growing and drive this group as generics become a smaller part of the business.
But branded drugs are moving the needle in the right direction. Teva's top-selling drug, Austedo, grew 41% to $559 million. Austedo is a treatment for tardive dyskinesia, a condition that causes involuntary facial movements. Management anticipates Austedo hitting $2.4 billion to $2.55 billion in sales for the full year, up from $2.26 billion in 2025.
Nearly all of Teva's other branded products are much smaller right now, but are growing at double-digit rates.
NameSales in Q1 2026Year-Over-Year Growth in Q1 2026Ajovy$87 million64%Copaxone$62 million16%Uzedy$63 million62% Source: Table created by author. Data from Teva Pharmaceutical Industries Q1 2026 earnings.
Becoming a better business for the long term Revenue growth might not jump off the page right away. Despite the impressive growth in these branded sales, Teva expects total revenue to fall from $17.3 billion in 2025 to $16.4 billion to $16.8 billion this year. The key difference here is that these are higher-quality dollars. Management is guiding for 30% operating margins in 2027 as branded sales continue to grow, up from only 12.5% last year.
Teva's biosimilars portfolio is gaining momentum, with sales expected to reach $800 million in 2027, more than offsetting lower generic sales. Additionally, Teva is bolstering its pipeline through acquisition. It recently bought Emalex Biosciences for $700 million, adding ecopipam, a developmental treatment for Tourette's syndrome in children, to its portfolio. Teva filed a New Drug Application with the U.S. Food & Drug Administration for ecopipam last month, following positive data from its Phase 3 clinical trial.
Teva's price targets are attainable At roughly $31 per share, Teva is trading at 14 times Wall Street's 2026 earnings estimates, and only 10 times 2027 estimates. The leap in earnings from this year to next is likely due to the expectation of those 30% operating margins, as reiterated by management on the company's Q1 earnings call.
That's a pretty inexpensive valuation for a company that suddenly has a lot going for it. Assuming ecopipam hits the market and branded and biosimilar sales continue to grow, Teva should be able to sustain solid earnings growth beyond next year. The low valuation leaves tons of room for that to translate to tangible investment returns.
TEVA data by YCharts. EPS = earnings per share.
If Teva delivers results that boost the market's sentiment toward the stock, even trading at just 15 times 2027 earnings estimates puts the share price above Wall Street's median price target of $40. So, these targets are certainly possible if Teva's business continues to perform well.
Teva uvedla, že její anti-IL-15 protilátka přinesla ve 24týdenní studii fáze 1b u vitiliga povzbudivé výsledky. Firma plánuje letos zahájit studii fáze 2.
MarketBeat Week in Review – 02/03 - 02/07Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.
During a conference call, President and CEO Richard Francis called the data “a milestone” in Teva’s “Pivot to Growth” plan and said 2026 is expected to include eight key events for the company, up from a prior expectation of seven following the addition of an ecopipam NDA filing.
Get TEVA alerts:
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy NowFrancis said Teva’s pipeline includes several programs that the company believes could each become $1 billion products in their respective indications, including anti-IL-15, duvakitug, emricasan, DARI, ecopipam and olanzapine-related programs. He said Teva expects its innovative portfolio to generate $3.5 billion of revenue in 2026.
Vitiligo Study Shows Facial and Total Body Responses Eric A. Hughes, Teva’s EVP of Global R&D and Chief Medical Officer, said vitiligo is an autoimmune disease in which an immune reaction destroys melanocytes, leading to loss of pigmentation. He said the disease affects about 0.5% to 2% of the global population and carries a psychological burden, including anxiety, depression and social isolation.
2 Generic Drug Stocks Ready to Surge in 2025Hughes said the only FDA-approved treatment currently available is a topical therapy for patients with less than 10% body surface area involvement, leaving a need for systemic options that can treat the whole body.
The phase 1b study evaluated Teva’s anti-IL-15 antibody in approximately 38 patients. Participants received one subcutaneous dose at day zero and another at week 12, with efficacy measured at 24 weeks. Hughes said 66% of patients in the study had skin involvement greater than 10% of their body surface area.
Teva reported the following 24-week results after two doses:
42% of patients achieved F-VASI50, representing at least a 50% improvement in facial vitiligo. 21% of patients achieved F-VASI75, representing at least a 75% improvement in facial vitiligo. 7% of patients achieved T-VASI50, representing at least a 50% improvement in total body vitiligo. 75% of patients reported improvement in facial skin using the facial Patient Global Impression of Change score, with half of those reporting “much” to “very much” improvement. 55% of patients reported improvement in total skin using the total Patient Global Impression of Change score. Hughes said the patient-reported outcomes were particularly meaningful because patients monitor their skin daily and may be strongly affected by changes in appearance.
Company Highlights Quarterly Dosing Potential Hughes said Teva believes its anti-IL-15 antibody is differentiated by its potency, long half-life and target engagement. He described the molecule as “Teva-born” and said it was created by the same internal team that developed duvakitug.
According to Hughes, the antibody has a half-life of about 38 days. He said the company observed rapid suppression of free IL-15 levels in serum within one or two days, and at the top dose, suppression below the limit of quantitation extended to about 80 to 90 days. Based on those data, Hughes said dosing once per quarter is a “strong possibility.”
Hughes said the drug has been “very well tolerated” to date, with no safety signals seen so far. In response to an analyst question, he said Teva has followed patients from earlier studies for extended periods, including out to about 400 days in some phase 1 work, and has not seen adverse events associated with IL-15 rebound as levels return to baseline.
Teva Compares Data With Oral JAK Programs Hughes compared the phase 1b results with published data from upadacitinib, an oral JAK therapy that he said recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
He said Teva’s F-VASI50 result of 42% compared with 38% and 39% in the upadacitinib data he referenced. Teva’s F-VASI75 result of 21% compared with 19% and 14%, while its T-VASI50 result of 7% compared with 6% and 11%.
Hughes said Teva views the comparison as encouraging, particularly because its product is being developed as a subcutaneous injection given once every quarter. He contrasted that with daily oral JAK therapy, which he said carries a black box warning.
Phase 2 Plans and Additional Indications Teva said it has already met with the FDA and is incorporating the agency’s feedback into a phase 2 study expected to begin this year. Hughes said the company plans dose-ranging work in phase 2b and is discussing a seamless study design that could allow the program to move efficiently toward phase 3.
Hughes said Teva expects facial VASI and total VASI endpoints to be used in later-stage development, with baseline criteria likely to include greater than 0.5 on facial VASI and greater than five on total VASI. He also said Teva will continue monitoring phase 1b subjects out to 80 weeks.
Teva also emphasized potential applications for anti-IL-15 beyond vitiligo. Hughes said IL-15 may be relevant in alopecia areata, celiac disease, eosinophilic esophagitis and atopic dermatitis. The company expects proof-of-concept data from a phase 2a celiac disease study in the second half of the year.
That celiac study, Hughes said, includes about 50 patients in a placebo-controlled gluten challenge design. Patients receive either active treatment or placebo, then undergo a gluten diet challenge, with biopsies used to evaluate effects on gut histology. Hughes said the crypt depth-to-villus height ratio will be the most important readout.
Francis closed the call by saying the anti-IL-15 vitiligo data represent the second of eight expected milestones for Teva this year, with additional pipeline updates anticipated in the coming months.
About Teva Pharmaceutical Industries NYSE: TEVATeva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Teva získala exkluzivní globální práva na komercializaci biosimilárního kandidáta k Ocrevusu od Polpharma Biologics po regulačním schválení. Pokryje intravenózní i subkutánní formu v USA, Evropě, Brazílii, Kanadě, Austrálii, na Novém Zélandu, v Izraeli a Turecku.
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines.
TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities.
“This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and development capabilities creates a clear path to getting this medicine to patients who need more treatment options.”
Under the terms of the agreement, Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar candidate. Teva will be responsible for regulatory submissions and, upon approval, commercialization of the intravenous and subcutaneous formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey.
“This agreement is aligned with Teva’s Pivot to Growth strategy and our focus on expanding our biosimilars pipeline. With our global commercial footprint and deep expertise in complex medicines, we are well positioned to help bring this biosimilar candidate to patients,” said Yolanda Tibbe, Vice President, Global Head of Biosimilars at Teva.
This strategic agreement reinforces both organizations’ commitment to broadening access to biologic medicines while promoting the long-term sustainability of healthcare systems.
About ocrelizumab
Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, which are believed to play a role in the autoimmune activity associated with multiple sclerosis. Ocrevus® (ocrelizumab) is indicated for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. In the U.S., the intravenous formulation is marketed as Ocrevus®, while the subcutaneous formulation is marketed separately as Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq). In the EU, both formulations carry the single brand name Ocrevus®.
About Multiple Sclerosis
Multiple sclerosis is a chronic, unpredictable and progressive disease of the central nervous system, which includes the brain and spinal cord. In MS, the loss of myelin, the protective sheath surrounding nerve fibers, disrupts the transmission of electrical signals to and from the brain, leading to a wide range of symptoms.
MS affects people differently. Symptoms can fluctuate, with periods of worsening (relapses) followed by partial or full recovery (remission). Over time, some patients may also experience a gradual progression of disability.
Common symptoms include fatigue, weakness, numbness or tingling, walking difficulties, spasticity, dizziness, and vision problems, among others.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
About Polpharma Biologics
Polpharma Biologics International AG is a biopharmaceutical company focused on development and manufacturing of biosimilars for supply to global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch in strong collaboration with our global partners.
Our international team of senior experts has proven experience in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Working with trusted CDMOs and CROs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners ensure access for patients to these medicines worldwide.
Our mission is to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development. www.polpharmabiologics.com
Media Contact – Polpharma Biologics
Stephanie Deitzer
Lead Transformation & Communications
Polpharma Biologics International AG [email protected]
+41 78 600 53 59
Teva Cautionary Note Regarding Forward-Looking Statements
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute our collaboration agreement with Polpharma Biologics for the commercialization of its biosimilar candidate to ocrelizumab, upon regulatory approval; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-looking statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
1 Ocrevus® and Ocrevus Zunovo® are registered trademarks of Genentech, Inc. and/or F. Hoffmann-La Roche Ltd.
NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designationsEcopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.
“The NDA submission for ecopipam is a significant milestone for a potential first-in-class treatment option in pediatric Tourette syndrome,” said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer of Teva. “This reflects the momentum in our innovative pipeline through our recent acquisition of this important asset, and advances our Pivot to Growth strategy and commitment to bringing differentiated medicines for patients.”
The NDA submission is supported by positive Phase 3 data recently published in JAMA Neurology, which showed that ecopipam significantly delayed time to relapse compared with placebo in pediatric patients with Tourette syndrome who had achieved a clinical response during the open-label treatment period. In the study, ecopipam demonstrated a statistically significant benefit on the primary efficacy endpoint in pediatric patients (p = 0.008) and was generally well tolerated, with the most common adverse events related to ecopipam therapy including somnolence, insomnia, anxiety, fatigue and headache.
About Tourette Syndrome
Tourette syndrome is a chronic neuro-developmental disorder character by involuntary motor and vocal tics beginning in childhood, often between 5 and 10 years of age. For people living with Tourette syndrome, symptoms can be frequent, visible, and disruptive, affecting everyday life. Despite the current treatment options available, many patients continue to experience inadequate treatment control or treatment-limiting side effects, underscoring the need for additional options.
About ecopipam
Ecopipam is a first-in-class investigational therapy designed to block dopamine signaling at the D1 receptor. D1 receptor hypersensitivity may contribute to repetitive and compulsive behaviors associated with Tourette syndrome.
Ecopipam has received Orphan Drug and Fast Track designations from the FDA for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation is reserved for patient populations of 200,000 or fewer.
Results from the Phase 3 study in Tourette syndrome were recently published in JAMA Neurology. The primary efficacy endpoint in the study was time to relapse (based on YGTSS-TTS scale) for pediatric patients who were stable and responding to ecopipam. The study showed statistical significance between ecopipam and placebo for the primary efficacy endpoint in pediatric patients (p = 0.008). Ecopipam was generally well-tolerated in the study and the most common adverse events related to ecopipam therapy were somnolence (n = 24 [11.1%]), anxiety (n = 21 [9.7%]), headache (n = 21 [9.7%]), insomnia (n = 19 [8.8%]), tic (n = 17 [7.9%]), and fatigue (n = 14 [6.5%]).
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.
All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully develop, obtain regulatory approval for and commercialize ecopipam; our ability to successfully compete in the marketplace including our ability to develop and commercialize ecopipam and additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva oznámila, že údaje k Austedu XR a Austedu podporují jejich širší využití a mohou posílit podíl na trhu. V prvním čtvrtletí tržby vzrostly na 4 miliardy USD a EPS stoupl o 72 % na 0,31 USD.
Teva Pharmaceuticals (TEVA +3.14%) is morphing from a generic drug maker into one that develops more innovative -- and profitable -- drugs. The stock is up more than 10% this year, and more than 95% over the past year.
On June 8, the company released data regarding its therapies, Austedo and Austedo XR (extended relief), at the Psych Congress Elevate. The three-year study showed that while more than 50% of tardive dyskinesia patients saw symptom improvement in controlling involuntary movements within 15 weeks, an additional 23% achieved success with long-term treatment.
This means that Austedo XR may be able to expand beyond its approved use to treat the involuntary movements (chorea) of Huntington's disease. The company also released a study on June 5 showing that 60% to 71% of Huntington's disease chorea patients experienced improvement with Austedo or Austedo XR.
This data provides doctors with strong therapeutic justification to prescribe Austedo or Austedo XR over competitors, securing market share for years to come. Here's one more reason to buy Teva stock, and one reason not to.
Image source: Getty Images.
The company's pivot is becoming more profitable In the first quarter of 2026, the company reported revenue of $4 billion, up 2% year over year. Its innovative brands, Austedo, migraine med Ajovy, and long-acting schizophrenia therapy Uzedy, together grew revenue by 41% over the same period last year. Earnings per share (EPS) rose 72% year over year, to $0.31. The key point is that the company's new drugs are offsetting its declining generic sales.
Today's Change
(
3.14
%) $
1.01
Current Price
$
33.21
Meanwhile, the company's application for a long-acting version of olanzapine for once-monthly treatment of schizophrenia is currently under review by the Food and Drug Administration (FDA).
This structural pivot expanded Teva's non-GAAP gross profit margin to 52.9% in Q1. The company is generating healthy free cash flow, estimated at $2 billion to $2.4 billion this year, which is being actively used to pay down its heavy debt load.
In April, the Israeli pharma struck a deal to acquire Emalex Biosciences for $700 million upfront. This included ecopipam, a dopamine D1 receptor antagonist that's en route to an FDA submission for Tourette syndrome this year. The drug has already received FDA fast-track and orphan drug designations.
Disappointing guidance, supply issues Teva's overall full-year 2026 financial guidance disappointed Wall Street. The company projected total 2026 revenue of $16.4 billion to $16.8 billion -- representing flat to slightly negative growth compared to 2025. That helps explain why the stock has fallen more than 3% since Teva released its Q1 earnings on April 29.
This stagnation is primarily due to intense generic competition eating into other parts of the portfolio (such as the generic version of the cancer drug Revlimid) and a drop-off in one-time milestone payments from partnerships (such as Sanofi). Because Austedo XR is carrying so much weight on its shoulders, any future slowdown in its adoption could leave Teva with very few places to hide, capping the stock's near-term upside until its next-generation immunology pipeline begins to commercialize in 2027.
The other concern is that ongoing conflicts in the Middle East and the blockade of the Strait of Hormuz have disrupted the movement of active pharmaceutical ingredients, and rising energy costs make it more expensive to ship drugs.
It's still a company headed in the right direction The company's move to pursue growth is obviously paying off, and its innovative drugs target conditions with unmet needs, giving them less competition.
Teva received FDA approval in March for biosimilar Ponlimsi to treat osteoporosis and bone loss. The company's pipeline includes six additional biosimilars that are expected to receive regulatory decisions this year. One of the most promising is omalizumab, a biosimilar to Xolair, made by Novartis (NVS +0.79%) and Roche (RHHBY +2.50%) to treat chronic hives.
The stock is trading at less than 15 times forward earnings, and considering its potential catalysts this year, that still seems like a bargain.
